Acugraf
(Tacrolimus 0.5/1/2 mg Capsule)
Trusted Immunomodulator for Grafting
"Ensure Safest Grafting in Organ Transplantation"
Mode of Action:
First-line calcineurin inhibitor
Tacrolimus:
- It is a calcineurin inhibitor (CNI), inhibits T-cell proliferation by binding to FK 506 binding protein (FKBP).
- Is an immunosuppressive agent used for prophylaxis of organ rejection post-transplant. https://www.ncbi.nlm.nih.gov/books/NBK544318/
- Drug of choice for Organ Transplantation
- Offers better graft survival & has lower incidence of rejection
- Potent immunosuppressant compared to cyclosporin
- Offers better safety and efficacy profile
Clinical Benefits for Patients:
- Effective immunosuppressant & anti-inflammatory.
- It has more potent immunosuppressant properties compared with cyclosporin, inhibiting cell-mediated and humoral immune responses.
- Compared with cyclosporin, tacrolimus showed comparable or greater patient/graft survival rates in patients following kidney transplantation & liver allograft recipients (where cost savings associated with reduced hospitalisation costs were evident in one study). https://www.ncbi.nlm.nih.gov/books/NBK544318/
- It is effective and well tolerated as a second-line therapy in patients with Autoimmune hepatitis
(AIH). Dig Dis Sci. 2021 Aug;66(8):2826-2832.
Rx for:
- Prophylaxis of organ rejection post-transplant
- Liver, Heart, Kidney & Lung Transplantation
- Autoimmune hepatitis (AIH)
Dosage:
- As directed by the Surgeon & Physician